Skip to main content

Table 1 Patient, cirrhosis, tumor, and surgical characteristics

From: Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy

 

Surgery (n = 32)

TACE (n = 16)

SIRT (n = 12)

P

Male sex, n (%)

19 (65.5%)

14 (87.5%)

11 (91.5%)

0.075

Mean age in years (median, range)

69.5 (65.5, 27–83)

67 (65.1, 29–88)

64 (62.6, 44–73)

0.8

Cause of cirrhosisa, n (%)

 Alcohol

11 (34.5%)

7 (43.75%)

3 (25%)

0.75

 Virus

13 (40.5%)

9 (56.25%)

8 (66.5%)

0.5

 HCV

8 (25%)

7 (43.75%)

7 (58.5%)

 

 HBV

3 (9.5%)

2 (12.5%)

1 (8.5%)

 

 HBV + HCV

2 (6.25%)

0

0

 

 Other

4 (12.5%)

2 (16.5%)

1 (8.5%)

 

 Mean MELD (median, range)

8.7 (7.9, 6.4–18.6)

9.1 (9.1, 6.4–13.8)

6 (7.7, 6–9.1)

0.2

 Mean tumor number (median, range)

1.1 (1, 1–3)

1.3 (1, 1–3)

1.7 (1, 1–2)

0.4

 Mean tumor diameter (mm) (median, range) mm

53.5 (40, 13–150)

59.6 (49.5, 30–150)

61.6 (47.5, 18–150)

0.75

 Mean AFP level (ng/ml) (median, range)

571 (19.7, 2–9900)

4267 [195, 1–69,000)

10,883 (38.5, 3–121,000)

0.281

 AFP > 400 ng/ml

3 (9.5%)

5 (31.25%)

3 (25%)

0.36

 Laparoscopic resection

11 (34.5%)

6 (37.5%)

4 (33.5%)

0.96

 Major resection

5 (15.5%)

11 (68.75%)

3 (25%)

0.006

 Operative mortality

1 (3.1%)

1 (6.25)

0

 

 Operative morbidity

13 (40.5%)

7 (43.75%)

5 (41.5%)

0.5

 0

19 (59.5%)

9 (56.25%)

7 (58.3%)

 

 1

4 (12.5%)

0

1 (8.5%)

 

 2

5 (15.5%)

5 (31.25%)

3 (25%)

 

 3a

2 (6.25%)

1 (6.25%)

1 (8.5%)

 

 3b

2 (6.25%)

1 (6.25%)

0

 

 4

0

0

0

 
  1. aSome patients could have several causes of cirrhosis
  2. TACE transarterial chemoembolization, SIRT selective internal radiation therapy, HBV hepatitis B virus, HCV hepatitis C virus, MELD model for end-stage liver disease, AFP alpha-fetoprotein